+44(0)208 9952500 karen.stancombe@lionsdencommunications.com LionsDen Communications Lionsden medical John Clare

The Pfizer bid for AZ

The Pfizer bid for AZ  be over, as least for now. However the ramifications are huge, particularly for both CEOs. Soriot will now be under great pressure from investors to deliver the new drugs he promised, and get the share price close to the £55 offered by Pfizer asap. For Read it’s a humiliating and public slap in the face. How did he get it so wrong? And what will be the US consequences of announcing he wants to move to Europe to keep the Pfizer cash pile out of the hands of the IRS?  Much more action to come, methinks.

http://www.in-pharmatechnologist.com/Processing/AstraZeneca-once-again-rejects-sweetened-Pfizer-takeover-bid

  • LinkedIn
  • Twitter
  • Facebook
  • StumbleUpon
  • Tumblr
  • Google Bookmarks
Leave a Reply

There are currently no comments.